Levsin injection recalled for manufacturing quality program discontinuation
Viatris Inc. is recalling Levsin injection (hyoscyamine sulfate, 0.5 mg/ml) due to discontinuation of the quality assurance program that verifies product identity, strength, quality, and purity. The recall affects 2,736 boxes distributed to 10 distributors.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This Class II recall involves a risk-of-harm product (injectable pharmaceutical) where the manufacturer's quality assurance program has been discontinued. The CGMP deviation affects the product's ability to assure identity, strength, quality, and purity characteristics, warranting High severity per the rubric for risk-of-harm products.
Plain-English summary
Viatris Inc. is recalling Levsin injection (hyoscyamine sulfate injection, USP, 0.5 mg per ml) because the manufacturer discontinued its quality assurance program. This program normally ensures the product meets the identity, strength, quality, and purity characteristics it is supposed to possess.
The affected product consists of 1 ml ampules supplied in boxes of 5, with lot number 101241A and expiration date October 2023. Approximately 2,736 boxes were distributed to 10 distributors who may have further distributed the product to retail locations.
The FDA has classified this as a Class II recall. The discontinuation of the quality program constitutes a Current Good Manufacturing Practice (CGMP) deviation.
The recalled product
- Product
- Levsin injection (hyoscyamine sulfate injection, USP), 0.5 mg per ml in water for Injection, 1 ml Ampule (Box of 5 ampules), Rx Only, Distributed by: Meda pharmaceuticals Inc. (a Viatris company) Somerset New Jersey 00873-4120, NDC #0037-9001-05
- Manufacturer
- Viatris Inc
- Category
- Drug
- Affected units
- 2,736
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 101241A
- Exp 10/23
Distribution
Distribution scope not specified by the agency.
Related recalls
Same manufacturer · Viatris Inc
See all →- HighXanax XR 3 mg extended-release tablets fail dissolution specifications
FDA (Drugs) · 2026-04-15
- ModeratePrescription Drug Cardura XL Recalled for Out-of-Specification Impurity
FDA (Drugs) · 2025-01-22
- HighPrescription Drug Cardura Recalled for Specification Failures in Manufacturing
FDA (Drugs) · 2025-01-22
- HighLevothyroxine Sodium Tablets recalled nationwide for potency failures
FDA (Drugs) · 2024-12-18
- HighLevothyroxine Sodium Tablets Recalled Due to Potency Failures
FDA (Drugs) · 2024-12-18
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- SevereShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate USP Recalled for CGMP Deviations Noted During FDA Inspection
FDA (Drugs) · 2026-08-19